DMAC — DiaMedica Therapeutics Share News
0.000.00%
Last trade - 00:00- $513.37m
- $469.88m
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program
DiaMedica rises after FDA feedback clears path for preeclampsia drug study
Brief: Diamedica Therapeutics Announces 75% Enrollment Milestone In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q1 net, operating income miss estimates; R&D costs to rise moderately
Brief: DiaMedica Therapeutics Receives Health Canada Clearance To Initiate Phase 2 Study Of Dm199 In Preeclampsia
Brief: Diamedica Therapeutics Provides Dm199 Preeclampsia Program Update
DiaMedica Therapeutics' Q3 net loss widens
Brief: DiaMedica Announces Inducement Grants Under Nasdaq Listing
DiaMedica Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
DiaMedica Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Diamedica Therapeutics Appoints Julie Krop, MD, As Chief Medical Officer
Brief: Diamedica Therapeutics To Report Second Quarter 2025 Financial Results And Provide A Business Update August 13, 2025
DiaMedica Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: DiaMedica Therapeutics Announces Poster Presentation At European Stroke Organisation Conference – ESOC 2025
DiaMedica Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights